TD Cowen provided analyst estimates for US sales while the FDA continues to regulate drug approval in the US market.
1 report, 0 independent
Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen provided analyst estimates for US sales while the FDA continues to regulate drug approval in the US market.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Analyst inquiries to Organon & Co. management covered competition risk, share repurchases, and sales targets.Sub-event
- TD Cowen downgraded Sarepta Therapeutics stock due to increased probability of drug withdrawal pending FDA approval.Sub-event
- TD Cowen released analyst estimates amid ongoing FDA drug approval regulations.
Keep exploring
The entities involved
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- TD Cowen raised its price target for HCA Healthcare, Inc. on October 23, 2026.
- TD Cowen raised its price target for Celcuity Inc., which saw a stock price increase driven by a bullish rating.
- Both the FDA and the European Medicines Agency govern drug approval processes.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
Coverage
Newest first; wire copies grouped- Unknown outlet